Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Clobetasol/omalizumab/prednisone

Maternal exposure during pregnancy, lack of efficacy and off-label use: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Konstantinou MP, et al. Successful treatment of recalcitrant pemphigoid gestationis with omalizumab: report of two cases. Journal of the European Academy of Dermatology and Venereology 36: e720-e722, No. 9, Sep 2022. Available from: URL: http://doi.org/10.1111/jdv.18227 Konstantinou MP, et al. Successful treatment of recalcitrant pemphigoid gestationis with omalizumab: report of two cases. Journal of the European Academy of Dermatology and Venereology 36: e720-e722, No. 9, Sep 2022. Available from: URL: http://​doi.​org/​10.​1111/​jdv.​18227
Metadaten
Titel
Clobetasol/omalizumab/prednisone
Maternal exposure during pregnancy, lack of efficacy and off-label use: case report
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25399-5

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Pentobarbital

Case report

Multiple drugs

Case report

Multiple drugs